opioid dependence

Abstract Background and aims Chronic non-cancer pain (CNCP) is one of the most common causes of disability globally. Opioid prescribing to treat CNCP remains widespread, despite limited evidence of long-term clinical benefit and evidence of...

Background: The COVID-19 pandemic has impacted how people access medications for opioid dependence. Researchers looked at monthly changes in several factors related to buprenorphine/naloxone (BNX) treatment over 56 months, including before...

Abstract Objective Methadone coverage is poor in many countries due in part to methadone induction being possible only in specialized care (SC). This multicenter pragmatic trial compared the effectiveness of methadone treatment between two...

ISSUP Kazakhstan presents Its webinar on the principles of harm reduction for patients. This webinar delves deeper into opioid agonist maintenance therapy.

For Immediate Release: May 23, 2023 Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD)...

Document of the Ministry of Health and Social Protection of Colombia that presents baseline of the maintenance programs with methadone in the country and the profile of the population served and the general characteristics of the treatment...

Abstract Importance: Patient-reported outcomes in the treatment of opioid dependence may differ between subcutaneously administered depot buprenorphine and daily sublingual buprenorphine. Objective: To compare patient satisfaction between...

Source: Silva, T.C., Andersson, F.B. The “black box” of treatment: Patients’ perspective on what works in opioid maintenance treatment for opioid dependence. Subst Abuse Treat Prev Policy 16, 41 (2021). https://doi.org/10.1186/s13011-021...